Guilford Gliadel Survival Data Could Address FDA “Non-Approvable” Letter
This article was originally published in The Gray Sheet
Executive Summary
Guilford Pharmaceuticals may submit Gliadel Wafer patient survival data to help address concerns outlined in FDA's "non-approvable" letter for newly diagnosed malignant glioma
You may also be interested in...
Guilford Gliadel Wafer Initial Surgery Indication To Launch In First Quarter
Guilford Pharmaceuticals anticipates approval of Gliadel Wafer for newly diagnosed malignant glioma by the end of March
Guilford Gliadel Wafer Initial Surgery Indication To Launch In First Quarter
Guilford Pharmaceuticals anticipates approval of Gliadel Wafer for newly diagnosed malignant glioma by the end of March
Guilford’s Gliadel Wafer
Recent Phase III long-term survival results for the Gliadel Wafer should reverse a non-approvable decision by FDA on a supplemental new drug application, Guilford claims. A March 2002 non-approvable letter from CMS stated the 23% reduction in risk of death with the primary brain cancer treatment was not statistically significant (1"The Gray Sheet" March 25, 2002, p. 12). Recent results show the device reduces the risk of death by 27% over three to four years...